New Findings Show UroLift System Same-Day Outpatient Procedure Demonstrates Symptom Improvement for Benign Prostatic HyperplasiaRead More
WAYNE, Pa., – October 28 2020 – Teleflex Incorporated (NYSE: TFX) today announced the expansion of its UroLift® System portfolio with the introduction of the UroLift® Advanced Tissue Control (ATC)™ System. The new system, which builds on the highly successful UroLift System, features a number of enhancements to enable urologists to more easily treat benign prostatic hyperplasia (BPH) patients with challenging anatomies, including an obstructive median lobe and large lateral lobes. The UroLift ATC System will be launched on a limited basis while the business unit expands its capacity to meet demand.
The UroLift ATC System was cleared by the U.S. Food and Drug Administration (FDA) in June 2020 to treat BPH, including lateral and median lobe hyperplasia, in prostates up to 100cc in men 45 years of age or older. The standard UroLift System was previously cleared by the FDA in late 2017 for median lobes. Although only a small percentage of patients have an obstructive median lobe, the UroLift ATC System further enhances the ability to treat these anatomies.
The new UroLift ATC System delivers the same proven UroLift implant through an enhanced delivery device tip. It features tissue control wings that hold tissue during manipulation, enabling the urologist to mobilize obstructive tissue and pin it to the side to enhance visualization and open up the blockage caused by the enlarged prostate. The tissue control wings are strategically shaped to optimize the view of obstructing tissue. The UroLift ATC System also includes a needle location marker with laser-etched markings that can aid with targeting accuracy for predictable implant placement.
“We are encouraged by early positive responses from urologists to the UroLift ATC System. Urologists are reporting high satisfaction with its ease of use and indicating their willingness to adopt the new device in their practices to treat patients with challenging anatomies, including obstructive median lobe and large lateral lobes,” said Dave Amerson, president of the Teleflex Interventional Urology business unit.
“My experience with the UroLift ATC System has been overwhelmingly positive,” said Steven Gange, M.D.+, Salt Lake City, Utah. “The new design features of the UroLift ATC System make it easier for me to treat patients with complex anatomies, and especially increase my confidence in treating patients with an obstructive median lobe.”
The UroLift System has consistently achieved statistically significant results in patients with an obstructive median lobe; the new UroLift ATC System will make it easier to handle the more complex anatomy of these patients. Data published from the MedLift Study showed that patients who were treated for obstructive median lobe with the standard UroLift System experienced significant improvements in IPSS (International Prostate Symptom Score), Qmax (peak flow rate), and QoL (quality of life) scores:1
Minimally Invasive, Same-Day Outpatient Procedure Provides Rapid Symptom Relief and RecoveryRead More
Data Presented at European Association of Urology Highlights Safety and Versatility of the Minimally Invasive UroLift System in a Real-World SettingRead More
Data Shows Minimally Invasive Treatment Provides Rapid Symptom Relief, Allowing Men to Return to Daily Activities QuicklyRead More
Free, Online Presentation to Address Symptoms of Enlarged Prostate, Treatment Options and Tips for Managing Condition During Pandemic
WAYNE, PA.— June 8, 2020—Teleflex Incorporated (NYSE: TFX) today announced that the company will host a free community health talk to discuss the symptoms, diagnosis and treatment options for enlarged prostate, also known as Benign Prostatic Hyperplasia (BPH). Dr. Wayne Kuang* will lead the webinar which can be viewed live on Wednesday, June 17 at 8:00 a.m. PDT and again at 4:30 p.m. PDT. Men and / or their partners from anywhere in the U.S. can attend the event.
BPH is a non-cancerous enlargement of the prostate that occurs as men age. This common condition is marked by bothersome urinary symptoms that can cause loss of productivity, depression, interrupted sleep and decreased quality of life.1 If left untreated, the condition can worsen over time and cause permanent bladder damage.2
“We are excited to offer our first ever virtual community health talk – a result of our efforts to stay connected with our patient community during the current pandemic,” said Dave Amerson, president of Teleflex Interventional Urology business unit. “Maintaining health is top of mind for many of us as we continue to navigate life in the midst of a pandemic. Our aim is to share information about BPH to a broad audience so that men who may be suffering from symptoms have accurate and reliable information they need to make informed decisions for their health.”
“As providers, we are dedicated to empowering our patients to get the information they need to make informed decisions about their health during this unprecedented time,” said Dr. Wayne Kuang, MD For Men, Albuquerque, NM. “Our goal for this timely webinar during Men’s Health Month is to provide attendees with a better understanding of how to address the challenges of an enlarged prostate – a condition that affects more than 40 million men in the U.S. alone3,4– and provide information about treatment solutions, such as the UroLift® System, for those experiencing BPH symptoms.”
Register to participate in this informative webinar by following this link: www.UroLift.com/seminar.
About the UroLift System
The FDA-cleared UroLift System is a proven, minimally invasive technology for treating lower urinary tract symptoms due to benign prostatic hyperplasia (BPH). The UroLift permanent implants, delivered during a minimally invasive transurethral outpatient procedure, relieve prostate obstruction and open the urethra directly without cutting, heating, or removing prostate tissue. Clinical data from a pivotal 206-patient randomized controlled study showed that patients with enlarged prostate receiving UroLift implants reported rapid and durable symptomatic and urinary flow rate improvement without compromising sexual function.**3,4 Patients also experienced significant improvement in quality of life. Over 175,000 men have been treated with the UroLift System worldwide.*** Most common adverse events reported include hematuria, dysuria, micturition urgency, pelvic pain, and urge incontinence. Most symptoms were mild to moderate in severity and resolved within two to four weeks after the procedure. The Prostatic Urethral Lift procedure (using the UroLift System) is recommended for the treatment of BPH in both the American Urological Association and European Association of Urology clinical guidelines. The UroLift System is available in many markets worldwide. Learn more at www.UroLift.com.
About Teleflex Interventional Urology
The Teleflex Interventional Urology Business Unit is dedicated to developing innovative, minimally invasive and clinically effective devices that address unmet needs in the field of urology. Our focus is on improving the standard of care for patients with BPH using the UroLift System, a minimally invasive permanent implant system that treats symptoms while preserving sexual function.**4,5 Learn more at www.NeoTract.com.
About Teleflex Incorporated
Teleflex is a global provider of medical technologies designed to improve the health and quality of people’s lives. We apply purpose driven innovation – a relentless pursuit of identifying unmet clinical needs – to benefit patients and healthcare providers. Our portfolio is diverse, with solutions in the fields of vascular and interventional access, surgical, anesthesia, cardiac care, urology, emergency medicine and respiratory care. Teleflex employees worldwide are united in the understanding that what we do every day makes a difference. For more information, please visit www.Teleflex.com.
Teleflex is the home of Arrow®, Deknatel®, Hudson RCI®, LMA®, Pilling®, Rusch®, UroLift® and Weck® – trusted brands united by a common sense of purpose.
Data Presented at American Urological Association 2020 Virtual Experience Highlight Benefits and Superior Sexual Function* Preservation of the Minimally Invasive Treatment for Patients with Enlarged ProstateRead More
Minimally Invasive Treatment for Enlarged Prostate Provides Rapid Relief1 and Durable Results2
WAYNE, Pa.— March 11, 2020—Teleflex Incorporated (NYSE: TFX) today announced that 175,000 patients have now been treated globally* with its minimally invasive UroLift® System—a safe and effective treatment for Benign Prostatic Hyperplasia (BPH) that provides rapid symptom relief and improved quality of life, while preserving sexual function.**1,3
BPH, also known as enlarged prostate, is a non-cancerous enlargement of the prostate that occurs as men age. This common condition is marked by bothersome urinary symptoms, such as getting up frequently at night to urinate, that can lead to loss of productivity, depression, and decreased quality of life.4 BPH affects over 40 million men in the United States alone.5 If left untreated, the condition can worsen over time and cause permanent bladder damage.6
Minimally Invasive Procedure Now Available to Hundreds of Thousands More Men with Enlarged Prostate, Providing Safe and Effective Symptom Relief.Read More
Minimally Invasive Treatment Options for BPH Remain Critical Due to Shortcomings of Surgery and MedicationRead More